Company: ARWR
Filing Date: 2025-11-18
Form Type: 8-K
Source: 0000879407-25-000019
Chunk: 0

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-11-18
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01

Other Events

OnNovember 18, 2025, Arro whead Pharmaceuticals, Inc. issued a press release announcing that the U. S. Food and Drug Administration has approved REDEMPLO®(plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). Arrowhead subsequently held a conference call discussing the approval.

A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference. A copy of the slides presented at the conference call is attached as Exhibit 99.2 to this Current Report and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                                                           
         99.1      Press Release, dated November 18, 2025.                                                               
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
         99.2      R E D E M PLO Approval Conf erence Call Nov ember 18, 2025                                            
          104      Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 18, 2025

  ARROWHEAD PHARMACEUTICALS, INC.                               
  By:                                  /s/ Daniel Apel          
                                       Daniel Apel              
                                       Chief Financial Officer